% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Chtelat:887675,
      author       = {Chételat, Gaël and Arbizu, Javier and Barthel, Henryk and
                      Garibotto, Valentina and Law, Ian and Morbelli, Silvia and
                      van de Giessen, Elsmarieke and Agosta, Federica and Barkhof,
                      Frederik and Brooks, David J and Carrillo, Maria C and
                      Dubois, Bruno and Fjell, Anders M and Frisoni, Giovanni B
                      and Hansson, Oskar and Herholz, Karl and Hutton, Brian F and
                      Jack, Clifford R and Lammertsma, Adriaan A and Landau, Susan
                      M and Minoshima, Satoshi and Nobili, Flavio and Nordberg,
                      Agneta and Ossenkoppele, Rik and Oyen, Wim J G and Perani,
                      Daniela and Rabinovici, Gil D and Scheltens, Philip and
                      Villemagne, Victor L and Zetterberg, Henrik and Drzezga,
                      Alexander},
      title        = {{A}myloid-{PET} and 18{F}-{FDG}-{PET} in the diagnostic
                      investigation of {A}lzheimer's disease and other dementias},
      journal      = {The lancet / Neurology},
      volume       = {19},
      number       = {11},
      issn         = {1474-4422},
      address      = {London},
      publisher    = {Lancet Publ. Group},
      reportid     = {FZJ-2020-04336},
      pages        = {951 - 962},
      year         = {2020},
      abstract     = {Various biomarkers are available to support the diagnosis
                      of neurodegenerative diseases in clinical and research
                      settings. Among the molecular imaging biomarkers,
                      amyloid-PET, which assesses brain amyloid deposition, and
                      18F-fluorodeoxyglucose (18F-FDG) PET, which assesses glucose
                      metabolism, provide valuable and complementary information.
                      However, uncertainty remains regarding the optimal
                      timepoint, combination, and an order in which these PET
                      biomarkers should be used in diagnostic evaluations because
                      conclusive evidence is missing. Following an expert panel
                      discussion, we reached an agreement on the specific use of
                      the individual biomarkers, based on available evidence and
                      clinical expertise. We propose a diagnostic algorithm with
                      optimal timepoints for these PET biomarkers, also taking
                      into account evidence from other biomarkers, for early and
                      differential diagnosis of neurodegenerative diseases that
                      can lead to dementia. We propose three main diagnostic
                      pathways with distinct biomarker sequences, in which
                      amyloid-PET and 18F-FDG-PET are placed at different
                      positions in the order of diagnostic evaluations, depending
                      on clinical presentation. We hope that this algorithm can
                      support diagnostic decision making in specialist clinical
                      settings with access to these biomarkers and might stimulate
                      further research towards optimal diagnostic strategies.},
      cin          = {INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-2-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572) / 573 -
                      Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-572 / G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {33098804},
      UT           = {WOS:000581121200027},
      doi          = {10.1016/S1474-4422(20)30314-8},
      url          = {https://juser.fz-juelich.de/record/887675},
}